It’s been quite a while since I talked about ex-vivo lung perfusion, but this was an interesting advance I saw posted a few days ago from the Pulmonary Fibrosis News website.
This actually improves on existing ex-vivo lung perfusion (EVLP) technology by using gene & cell therapy to rehabilitate & repair lungs that would otherwise be unsuitable for transplant.
This Business Wire press release gives more information on the companies involved & this exciting news.
Hopefully the successes of these companies in Toronto will soon be crossing the border to us soon.
In my first week blogging I talked about an advancement called ex-vivo lung perfusion, or “lung in a box” technology as a way to make “marginal lungs” viable for transplant. For all you science geeks like me, here’s a video of it in action from an actual operating table. Warning: Viewing is not for the squeamish.
In my blog post from 8/4/15, I talked about a transplant innovation called ex-vivo lung perfusion (EVLP). If you missed that post, you may want to go back & read it before reading this one. (I just linked to it if you need bounce back).
In my past post, Deeper Questions, I mentioned that my transplant center, Hospital of the University of Pennsylvania (UPENN) uses a technology called ex-vivo lung perfusion to make transplanted lungs more viable, allowing them to be sustained outside the body for longer periods, & potentially reversing damage that might have once caused lungs to not be suitable for transplant. They have some excellent information at the website as part of the lung transplant program page that outlines this technology (in fact, that’s where I found the image I used to accompany this post) what exactly it is, & how it’s led to more transplants & better outcomes.